Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Autologous T-cell therapy for metastatic renal cell carcinoma
E. T. Goluboff
, J. M. McKiernan
, I. S. Sawczuk
Research output
:
Contribution to journal
›
Article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Autologous T-cell therapy for metastatic renal cell carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Cimetidine
100%
Autologous T Cell Therapies
100%
Median Survival
66%
Mean Survival Time
33%
Curative Treatment
33%
Monotherapy
33%
Survival Benefit
33%
Peripheral Blood
33%
Tumor Response
33%
Low Toxicity
33%
Adoptive Immunotherapy
33%
Therapy Groups
33%
Study Termination
33%
Blood-derived
33%
Autologous T Cells
33%
Medicine and Dentistry
Kidney Metastasis
100%
Cell Therapy
100%
T Cell
100%
Cimetidine
100%
Neoplasm
33%
Monotherapy
33%
Outpatient
33%
Arm
33%
Group Therapy
33%
Ex Vivo
33%
Adoptive Immunotherapy
33%
Median Follow Up
33%